Back to News
Vitex-appoints-Dr-Aniss-G.E.Chami-as-CEO-of-Vitex-Pharmaceuticals_01032016-1.pdf (143 KB)

1 March 2016, Sydney, Australia: Vitex Pharmaceuticals has announced the appointment of Dr Aniss G.E. Chami as its new Chief Executive Officer. Dr Chami, who currently serves as Vitex’s General Manager and Acting Quality Assurance Manager, will succeed Elie Chami, the company’s founder and current Managing Director effective 1 March, 2016.

In this position, Dr Chami will provide strategic and managerial leadership with the vision for the company to be Australia’s leading facility for manufacturing medicine. Elie Chami will continue as Executive Chairman to guide the development of the expansion to the new 22,000sqm state-of-the-art pharmaceutical facility in Sydney.

Announcing Dr Chami’s appointment Elie Chami said, “My son is an exceptional leader. He has been with me from day one building the foundations of this company and has been the driving force for a great portion of our success. I’m hugely proud of the company’s achievements to date and I’m confident that under his leadership, Vitex will continue to prosper and lead the way in its ongoing evolution to be Australia’s leading and largest pharmaceutical manufacturing facility.”

Dr Chami is widely regarded as an industry leader with unrivalled experience and qualifications. With over 15 years of experience in the industry, he is sought-after for his expertise and impressive academic background. Dr Chami graduated from Macquarie University completing his Bachelor of Medical Science with Honours (B Med Sci) (Hon). He went on to complete his Master of Pharmacy (MPharm) at the University of Sydney, before completing his Bachelor of Medicine and Bachelor of Surgery (MBBS) at the Sydney School of Medicine (UND). Dr Chami also holds a Master’s Degree in Financial Management (MFM) and a Master’s Degree in Business Administration (MBA) at the prestigious world-ranking Macquarie Graduate School of Management.

With a remarkable list of credentials, Dr Chami is also one of the youngest CEOs in the industry. Unequivocally, however, he is considered to be one of the most experienced – having been immersed at an early age under his father’s guidance and support together with the industry founders who have made significant contributions to manufacturing complementary medicine in Australia.

“My father has built a legacy of quality and trust in this industry. Through discussions with our partners and industry stakeholders locally and throughout the world, it is evident just how important the reputation of high quality Australian-made medicine is in leading the future of manufacturing and the growth of the local economy. As one of the very few Australian-owned and operated contract manufacturers in this industry, we take this responsibility seriously because we recognise the impact our business has on our community, clients and consumers,” said Dr Chami.

“It is with great honour and excitement to have the opportunity to lead the business into the future and preserve my father’s legacy. Our proposition for quality, integrity and innovation resonates with our clients. It is with this ethos that we are on the trajectory to realise our vision to represent Australia in the global landscape as the benchmark for pharmaceutical manufacturing excellence,” concluded Dr Chami.